Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:30:19 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:CPRX - CATALYST PHARMACEUTICALS INC - https://www.copper-ridge.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CPRX - Q0.321.04·21.551.521.45+0.271.31,411.829,57612,57621.18  21.535  21.0526.58  15.34Jul 17Jun 0215 min RT 2¢

Recent Trades - Last 10 of 12576
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-02 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
2025-05-07 16:15U:CPRXNews ReleaseCatalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
2025-04-30 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
2025-04-22 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
2025-04-08 08:07U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE(TM) New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
2025-03-04 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
2025-02-26 16:13U:CPRXNews ReleaseCatalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2025-02-12 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
2025-01-23 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
2025-01-21 08:19U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE(TM) in Japan
2025-01-08 12:30U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Settlement of FIRDAPSE(TM) (amifampridine) Patent Litigation with Teva Pharmaceuticals
2024-12-16 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2024-11-25 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500(TM) List
2024-11-19 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
2024-11-13 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
2024-11-06 16:12U:CPRXNews ReleaseCatalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
2024-10-22 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
2024-10-08 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
2024-10-01 08:03U:CPRXNews ReleaseCatalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
2024-09-24 06:00U:CPRXNews ReleaseCatalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE(TM) in Japan